120 related articles for article (PubMed ID: 9581607)
1. Assessment of glucosylifosfamide mustard biodistribution in rats with prostate adenocarcinomas by means of in vivo 31P NMR and in vitro uptake experiments.
Haberkorn U; Krems B; Gerlach L; Bachert P; Morr I; Wiessler M; van Kaick G
Magn Reson Med; 1998 May; 39(5):754-61. PubMed ID: 9581607
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat.
Stüben J; Port R; Bertram B; Bollow U; Hull WE; Schaper M; Pohl J; Wiessler M
Cancer Chemother Pharmacol; 1996; 38(4):355-65. PubMed ID: 8674159
[TBL] [Abstract][Full Text] [Related]
3. Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1.
Veyhl M; Wagner K; Volk C; Gorboulev V; Baumgarten K; Weber WM; Schaper M; Bertram B; Wiessler M; Koepsell H
Proc Natl Acad Sci U S A; 1998 Mar; 95(6):2914-9. PubMed ID: 9501190
[TBL] [Abstract][Full Text] [Related]
4. 31P NMR studies of the kinetics of bisalkylation by isophosphoramide mustard: comparisons with phosphoramide mustard.
Boal JH; Williamson M; Boyd VL; Ludeman SM; Egan W
J Med Chem; 1989 Aug; 32(8):1768-73. PubMed ID: 2754703
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics and stability of isophosphoramide mustard.
Zheng JJ; Chan KK; Muggia F
Cancer Chemother Pharmacol; 1994; 33(5):391-8. PubMed ID: 8306413
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the protonation of isophosphoramide mustard and phosphoramide mustard.
Millis KK; Colvin ME; Shulman-Roskes EM; Ludeman SM; Colvin OM; Gamcsik MP
J Med Chem; 1995 Jun; 38(12):2166-75. PubMed ID: 7783148
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide pharmacokinetics and hepatobiliary uptake in vivo investigated using single- and double-resonance 31P MRS.
Mancini L; Payne GS; Dzik-Jurasz AS; Leach MO
Magn Reson Med; 2003 Aug; 50(2):249-55. PubMed ID: 12876700
[TBL] [Abstract][Full Text] [Related]
8. Glufosfamide: beta-D-Glc-IPM, D 19575.
Drugs R D; 2005; 6(1):49-52. PubMed ID: 15801867
[TBL] [Abstract][Full Text] [Related]
9. In vivo detection of ifosfamide by 31P-MRS in rat tumours: increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas.
Rodrigues LM; Maxwell RJ; McSheehy PM; Pinkerton CR; Robinson SP; Stubbs M; Griffiths JR
Br J Cancer; 1997; 75(1):62-8. PubMed ID: 9000599
[TBL] [Abstract][Full Text] [Related]
10. Glufosfamide as a new oxazaphosphorine anticancer agent.
Mazur L; Opydo-Chanek M; Stojak M
Anticancer Drugs; 2011 Jul; 22(6):488-93. PubMed ID: 21427562
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the urinary excretion of ifosfamide and its N-dechloroethylated metabolites in children using 31P-NMR spectroscopy.
Misiura K; Zubowska M; Zielińska E
Arzneimittelforschung; 2003; 53(5):372-7. PubMed ID: 12854365
[TBL] [Abstract][Full Text] [Related]
12. Role of oxygen vs. glucose in energy metabolism in a mammary carcinoma perfused ex vivo: direct measurement by 31P NMR.
Eskey CJ; Koretsky AP; Domach MM; Jain RK
Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2646-50. PubMed ID: 8464871
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention.
Lokiec F
Ann Oncol; 2006 May; 17 Suppl 4():iv33-6. PubMed ID: 16702183
[TBL] [Abstract][Full Text] [Related]
14. Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells.
Smith SM; Ludeman SM; Wilson LR; Springer JB; Gandhi MC; Dolan ME
Cancer Chemother Pharmacol; 2003 Oct; 52(4):291-302. PubMed ID: 12845477
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients.
Boddy AV; Proctor M; Simmonds D; Lind MJ; Idle JR
Eur J Cancer; 1995; 31A(1):69-76. PubMed ID: 7695982
[TBL] [Abstract][Full Text] [Related]
16. Nuclear magnetic resonance and high-performance liquid chromatography-nuclear magnetic resonance studies on the toxicity and metabolism of ifosfamide.
Foxall PJ; Lenz EM; Lindon JC; Neild GH; Wilson ID; Nicholson JK
Ther Drug Monit; 1996 Aug; 18(4):498-505. PubMed ID: 8857575
[TBL] [Abstract][Full Text] [Related]
17. 31P-nuclear magnetic resonance spectroscopy in vivo of six human melanoma xenograft lines: tumour bioenergetic status and blood supply.
Lyng H; Olsen DR; Southon TE; Rofstad EK
Br J Cancer; 1993 Dec; 68(6):1061-70. PubMed ID: 8260356
[TBL] [Abstract][Full Text] [Related]
18. Biodegradability of antineoplastic compounds in screening tests: influence of glucosidation and of stereochemistry.
Kümmerer K; al-Ahmad A; Bertram B; Wiessler M
Chemosphere; 2000 Apr; 40(7):767-73. PubMed ID: 10705555
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo.
Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T
Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637
[TBL] [Abstract][Full Text] [Related]
20. Effects of chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea on single-quantum- and triple-quantum-filtered 23Na and 31P nuclear magnetic resonance of the subcutaneously implanted 9L glioma.
Winter PM; Poptani H; Bansal N
Cancer Res; 2001 Mar; 61(5):2002-7. PubMed ID: 11280759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
